Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer

Launched by UNIVERSITY OF OKLAHOMA · Apr 28, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how a mobile health platform can help monitor symptoms and assess the quality of life for patients with recurrent head and neck cancer. The study aims to improve the way we track patients' experiences and side effects during treatment. It is currently recruiting participants who are at least 18 years old and have been diagnosed with head and neck cancer that has returned or spread and cannot be treated with curative methods. Participants should have had at least six months since their last radiation therapy, and they need to be in fairly good health, as determined by their doctor.

If you join this trial, you will use a mobile app that helps keep track of your symptoms and overall well-being. Your participation will contribute to understanding how to better support patients like you during treatment. It's important to note that this study cannot accept individuals who have had recent radiation therapy to the same area or those who are pregnant, among other criteria. If you think you might be eligible, talk to your healthcare provider for more details.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years and older
• • Written informed consent and any locally-required authorization obtained from the patients prior to performing any protocol-related procedures, including screening evaluations
• • Pathologically (histologically or cytologically) proven diagnosis of cancer of the head and neck (nasopharynx, oral cavity, oropharynx, hypopharynx, larynx, or unknown primary) or Gynecologic cancers (cervical and endometrial)
• • Locally recurrent or metastatic HNC or Gyn cancer not deemed amenable to curative-intent salvage therapy, in whom at least six months have passed since their prior RT, if received
• • Must have evaluable lesion per RECIST v1.1
• • Patients agree to provide their smoking history prior to registration
• • ECOG performance status of 0-2
• Exclusion Criteria:
• • Prior radiotherapy to the region of the study cancer within less than 6 months
• • Patients who have received prior radiation therapy and who, in the opinion of the treating radiation oncologist, cannot be reirradiated safely without excess risk of severe toxicity given prior radiation dose to critical structures.
• • Patients with known contraindications to radiotherapy, including inherited syndromes associated with hypersensitivity to ionizing radiation (e.g., Ataxia-Telangiectasia, Nijmegen Breakage Syndrome)
• • Female patients who are pregnant